© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Hikma Pharmaceuticals PLC (HKMPY) stock surged +2.48%, trading at $43.43 on OTC, up from the previous close of $42.38. The stock opened at $43.43, fluctuating between $43.43 and $43.43 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Feb 02, 2026 | 41.84 | 43.43 | 41.84 | 43.43 | 411 |
| Jan 30, 2026 | 42.38 | 42.38 | 42.38 | 42.38 | 222 |
| Jan 26, 2026 | 41.85 | 43.93 | 41.85 | 43.93 | 774 |
| Jan 23, 2026 | 42.60 | 42.60 | 42.60 | 42.60 | 183 |
| Jan 22, 2026 | 42.35 | 42.35 | 42.35 | 42.35 | 450 |
| Jan 21, 2026 | 40.91 | 40.91 | 40.91 | 40.91 | 115 |
| Jan 20, 2026 | 41.39 | 41.39 | 41.33 | 41.33 | 1.52K |
| Jan 16, 2026 | 42.45 | 42.45 | 42.45 | 42.45 | 476 |
| Jan 15, 2026 | 43.04 | 43.04 | 43.04 | 43.04 | 328 |
| Jan 14, 2026 | 42.54 | 42.54 | 42.54 | 42.54 | 251 |
| Jan 12, 2026 | 42.00 | 42.53 | 42.00 | 42.53 | 2.82K |
| Jan 08, 2026 | 42.15 | 42.15 | 42.15 | 42.15 | 270 |
| Jan 07, 2026 | 42.49 | 42.50 | 42.44 | 42.50 | 4.7K |
| Jan 06, 2026 | 42.55 | 42.55 | 41.63 | 41.63 | 11.77K |
| Jan 05, 2026 | 41.66 | 41.66 | 41.59 | 41.59 | 771 |
| Jan 02, 2026 | 41.38 | 41.75 | 41.38 | 41.73 | 1.91K |
| Dec 31, 2025 | 41.92 | 41.93 | 41.92 | 41.93 | 682 |
| Dec 30, 2025 | 41.77 | 41.77 | 41.77 | 41.77 | 573 |
| Dec 29, 2025 | 42.00 | 42.00 | 40.93 | 40.93 | 2.48K |
| Dec 26, 2025 | 40.68 | 42.20 | 39.93 | 41.45 | 1.06K |
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
| Employees | 9500 |
| Beta | 0.73 |
| Sales or Revenue | $2.88B |
| 5Y Sales Change% | 0.497% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |